Once Daily I.v. Busulfan and Fludarabine (i.v. Bu-Flu) Compares Favorably with I.v. Busulfan and Cyclophosphamide (i.v. BuCy2) As Pretransplant Conditioning Therapy in AML/MDS

Overview

Journal Biol Blood Marrow Transplant

Date 2008 May 21

PMID 18489993

Citations 73

Authors

Borje S Andersson

Marcos de Lima

Peter F Thall

Xuemei Wang

Daniel Couriel

Martin Korbling

Soonja Roberson

Sergio Giralt

Betty Pierre

James A Russell

Elizabeth J Shpall

Roy B Jones

Richard E Champlin

Affiliations

Soon will be listed here.

Abstract

We postulated that fludarabine (Flu) instead of cyclophosphamide (Cy) combined with i.v. busulfan (Bu) as preconditioning for allogeneic hematopoietic stem cell transplantation (HSCT) would improve safety and retain antileukemic efficacy. Sixty-seven patients received BuCy2, and subsequently, 148 patients received Bu-Flu. We used a Bayesian method to compare outcomes between these nonrandomized patients. The groups had comparable pretreatment characteristics, except that Bu-Flu patients were older (46 versus 39 years, P < .01), more often had unrelated donors (47.3% versus 20.9%, P < .0003), and had shorter median follow-up (39.7 versus 74.6 months). To account for improved supportive care and other unidentified factors that may affect outcome ("period" effects), 78 acute myelogenous leukemia (AML) patients receiving Melphalan-Flu (MF), treated in parallel during this time (1997-2004) were used to estimate the period effect. The MF patients' outcomes worsened during this period. Therefore, the period effect is unlikely to explain the greatly improved outcome with Bu-Flu. Patients transplanted with Bu-Flu in the first complete remission (CR1) had a 3-year overall survival and event-free-survival (EFS) of 78% and 74%, respectively, whereas CR1 patients younger than age 41 had a 3-year EFS of 83%. These results support replacing BuCy +/- ATG with Bu-Flu +/- rabbit-antithymocyte globulin (ATG), and warrant a prospective comparison between allogeneic HSCT and conventional induction/consolidation chemotherapy for AML in CR1.

Citing Articles

High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas.

Ramdial J, Lin R, Thall P, Valdez B, Hosing C, Srour S Bone Marrow Transplant. 2024; 59(12):1754-1762.

PMID: 39341929 PMC: 11611727. DOI: 10.1038/s41409-024-02394-0.

Evaluate the Efficacy of Myeloablative Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myelogenous Leukemia at BTH, Vietnam.

Nguyen T, Huynh H, Tran H, Nguyen Q, Huynh P, Hoang N Int J Hematol Oncol Stem Cell Res. 2024; 18(3):254-261.

PMID: 39257712 PMC: 11381668. DOI: 10.18502/ijhoscr.v18i3.16106.

Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial.

Cavallaro G, Grassi A, Pavoni C, Mico M, Busca A, Cavattoni I Blood Cancer J. 2024; 14(1):141.

PMID: 39168989 PMC: 11339290. DOI: 10.1038/s41408-024-01116-5.

Evaluating clinically translatable conditioning for platelet gene therapy in murine hemophilia A with inhibitors.

Chen Y, Li J, Schroeder J, Jing W, Shi Q J Thromb Haemost. 2024; 22(11):3035-3047.

PMID: 39127324 PMC: 11513242. DOI: 10.1016/j.jtha.2024.07.023.

Across the Myeloablative Spectrum: Hematopoietic Cell Transplant Conditioning Regimens for Pediatric Patients with Sickle Cell Disease.

Limerick E, Abraham A J Clin Med. 2022; 11(13).

PMID: 35807140 PMC: 9267729. DOI: 10.3390/jcm11133856.

References

de Lima M, Champlin R, Thall P, Wang X, Martin 3rd T, Cook J . Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia. 2007; 22(2):258-64. DOI: 10.1038/sj.leu.2405014. View

Chang C, Storer B, Scott B, Bryant E, Shulman H, Flowers M . Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent.... Blood. 2007; 110(4):1379-87. PMC: 1939908. DOI: 10.1182/blood-2007-02-076307. View

Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W . Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall.... Biol Blood Marrow Transplant. 2002; 8(9):493-500. DOI: 10.1053/bbmt.2002.v8.pm12374454. View

Thall P, Champlin R, Andersson B . Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment.... Bone Marrow Transplant. 2004; 33(12):1191-9. DOI: 10.1038/sj.bmt.1704461. View

de Lima M, Couriel D, Thall P, Wang X, Madden T, Jones R . Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004; 104(3):857-64. DOI: 10.1182/blood-2004-02-0414. View

Korbling M, Huh Y, Durett A, Mirza N, Miller P, Engel H . Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood. 1995; 86(7):2842-8. View

McCune J, Batchelder A, Deeg H, Gooley T, Cole S, Phillips B . Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant. 2007; 13(7):853-62. DOI: 10.1016/j.bbmt.2007.03.012. View

Przepiorka D, Smith T, Folloder J, Khouri I, Ueno N, Mehra R . Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999; 94(4):1465-70. View

Marks D, Forman S, Blume K, Perez W, Weisdorf D, Keating A . A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant. 2006; 12(4):438-53. DOI: 10.1016/j.bbmt.2005.12.029. View

10.

Przepiorka D, Ippoliti C, Giralt S, van Beisen K, Mehra R, Deisseroth A . A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. Bone Marrow Transplant. 1994; 14(3):449-53. View

11.

de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C . Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004; 104(3):865-72. DOI: 10.1182/blood-2003-11-3750. View

12.

Vassal G . Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review). Anticancer Res. 1994; 14(6A):2363-70. View

13.

Williams C, Day S, Reed M, Copelan E, Bechtel T, Leather H . Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Biol Blood Marrow Transplant. 2004; 10(9):614-23. DOI: 10.1016/j.bbmt.2004.05.010. View

14.

McDonald G, Slattery J, Bouvier M, Ren S, Batchelder A, Kalhorn T . Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2002; 101(5):2043-8. DOI: 10.1182/blood-2002-06-1860. View

15.

Estey E, Thall P, Giles F, Wang X, Cortes J, Beran M . Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine.... Blood. 2002; 99(12):4343-9. DOI: 10.1182/blood.v99.12.4343. View

16.

Hassan M, Ljungman P, Ringden O, Hassan Z, Oberg G, Nilsson C . The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant. 2000; 25(9):915-24. DOI: 10.1038/sj.bmt.1702377. View

17.

Hallemeier C, Girgis M, Blum W, Brown R, Khoury H, Goodnough L . Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants. Biol Blood Marrow Transplant. 2004; 10(5):310-9. DOI: 10.1016/j.bbmt.2003.12.002. View

18.

Keating M, Smith T, Gehan E, McCredie K, Bodey G, Spitzer G . Factors related to length of complete remission in adult acute leukemia. Cancer. 1980; 45(8):2017-29. DOI: 10.1002/1097-0142(19800415)45:8<2017::aid-cncr2820450806>3.0.co;2-c. View

19.

Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A . Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia. 2005; 20(2):322-8. DOI: 10.1038/sj.leu.2404037. View

20.

Alyea E, Kim H, Ho V, Cutler C, DeAngelo D, Stone R . Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2006; 12(10):1047-55. DOI: 10.1016/j.bbmt.2006.06.003. View